comparemela.com

Latest Breaking News On - Accessed marc - Page 1 : comparemela.com

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

/PRNewswire/ Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating.

United statesPrnewswire johnsonLaura ferrisLloyd millerCraig stoltzProtagonist therapeutics incUniversity of pittsburghExchange commissionJanssen biotech incAmerican academy of dermatologyNone of janssen research developmentNational psoriasis foundationJanssen research developmentEveryday healthAmerican academyPsoriasis area

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only.

United statesCraig stoltzPrnewswire johnsonLloyd millerLaura ferrisJanssen research developmentJanssen biotech incEveryday healthAmerican academy of dermatologyUniversity of pittsburghExchange commissionNational psoriasis foundationNone of janssen research developmentProtagonist therapeutics incAmerican academyPsoriasis area

vimarsana © 2020. All Rights Reserved.